20 March 2013
Appearance of ANCA – associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment
Tatiana ReitblatABDF, Olga ReitblatCEFDOI: 10.12659/AJCR.883841
Am J Case Rep 2013; 14:80-82
Abstract
Background: Tumor necrosis factor-alpha inhibitors treatment is accosiated with several side effects. The most common are injection side reactions, headache, nausea and infections. The more rare are development of systemic autoimmune diseases.
Case Report: We describe two patients, who developed ANCA associated vasculitis during Tumor necrosis factor alpha inhibitors treatment. The diagnosis was confirmed by appropriate tissue picture, CT scan and laboratory findings.
Conclusions: Our case series are unique, because vasculitis appeared after many years of the treatment and during complete patient’s remission of there main illness.
Keywords: Tumor Necrosis Factor-alpha - antagonists & inhibitors, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Arthritis, Rheumatoid, Arthritis, Psoriatic
SARS-CoV-2/COVID-19
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936585
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935885
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934951
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936165
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744